Vital Therapies (NASDAQ:VTL) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Wednesday, January 31st.
VTL has been the topic of a number of other reports. ValuEngine raised Vital Therapies from a “strong sell” rating to a “sell” rating in a research report on Saturday, October 21st. Zacks Investment Research lowered Vital Therapies from a “hold” rating to a “sell” rating in a research report on Tuesday, October 31st. Finally, Raymond James Financial restated a “buy” rating on shares of Vital Therapies in a research note on Tuesday, December 5th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $6.00.
Shares of Vital Therapies (NASDAQ:VTL) opened at $5.03 on Wednesday. Vital Therapies has a twelve month low of $2.25 and a twelve month high of $6.70. The company has a market capitalization of $212.09, a P/E ratio of -3.75 and a beta of 4.75.
In related news, Director Muneer A. Satter acquired 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 13th. The shares were acquired at an average price of $5.48 per share, with a total value of $548,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Muneer A. Satter acquired 50,000 shares of the company’s stock in a transaction that occurred on Thursday, December 7th. The shares were bought at an average cost of $4.77 per share, for a total transaction of $238,500.00. The disclosure for this purchase can be found here. Insiders have bought a total of 300,000 shares of company stock valued at $1,520,000 in the last quarter. 32.60% of the stock is owned by corporate insiders.
Several large investors have recently added to or reduced their stakes in the business. Victory Capital Management Inc. raised its holdings in shares of Vital Therapies by 12.4% in the 4th quarter. Victory Capital Management Inc. now owns 2,925,886 shares of the company’s stock valued at $17,409,000 after acquiring an additional 322,797 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Vital Therapies by 136.2% during the 4th quarter. BlackRock Inc. now owns 990,828 shares of the company’s stock valued at $5,896,000 after buying an additional 571,418 shares in the last quarter. Granahan Investment Management Inc. MA raised its holdings in shares of Vital Therapies by 51.4% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 388,282 shares of the company’s stock valued at $1,961,000 after buying an additional 131,828 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Vital Therapies by 261.4% during the 2nd quarter. Goldman Sachs Group Inc. now owns 233,250 shares of the company’s stock valued at $676,000 after buying an additional 168,705 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Vital Therapies by 10.3% during the 4th quarter. Geode Capital Management LLC now owns 192,788 shares of the company’s stock valued at $1,147,000 after buying an additional 18,050 shares in the last quarter. 25.00% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Vital Therapies (VTL) Lifted to “Hold” at BidaskClub” was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://ledgergazette.com/2018/02/19/vital-therapies-vtl-upgraded-at-bidaskclub.html.
Vital Therapies Company Profile
Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.
Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.